Messenger RNA technology offers a faster way to develop vaccines to address or prepare for pandemics, and Moderna’s vaccine candidate for avian influenza is on track for Phase 3 testing. But the Department of Health and Human Services has canceled a $590 million contract to support Moderna’s pivotal trial.
The post Bird Flu Threat Still Looms, But HHS Just Canceled a Moderna Contract That Could Prepare for It appeared first on MedCity News.
